Compare Torrent Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DR. DATSONS LABS - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DR. DATSONS LABS TORRENT PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 57.8 -10.9 - View Chart
P/BV x 6.1 0.2 3,765.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
DR. DATSONS LABS
Mar-14
TORRENT PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs1,550126 1,234.1%   
Low Rs1,14431 3,700.6%   
Sales per share (Unadj.) Rs354.7133.0 266.7%  
Earnings per share (Unadj.) Rs40.10.2 26,432.4%  
Cash flow per share (Unadj.) Rs64.26.6 971.9%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.1128.8 212.1%  
Shares outstanding (eoy) m169.2231.66 534.5%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x3.80.6 645.3%   
Avg P/E ratio x33.6516.1 6.5%  
P/CF ratio (eoy) x21.011.8 177.1%  
Price / Book Value ratio x4.90.6 811.5%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8972,477 9,199.1%   
No. of employees `00014.7NA-   
Total wages/salary Rs m11,35356 20,272.3%   
Avg. sales/employee Rs Th4,083.0NM-  
Avg. wages/employee Rs Th772.3NM-  
Avg. net profit/employee Rs Th461.3NM-  
INCOME DATA
Net Sales Rs m60,0214,211 1,425.5%  
Other income Rs m2,98879 3,797.2%   
Total revenues Rs m63,0094,289 1,469.0%   
Gross profit Rs m13,493569 2,372.9%  
Depreciation Rs m4,086204 1,999.0%   
Interest Rs m3,085430 717.1%   
Profit before tax Rs m9,31013 73,307.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5296 41,454.1%   
Profit after tax Rs m6,7815 141,279.2%  
Gross profit margin %22.513.5 166.5%  
Effective tax rate %27.248.0 56.5%   
Net profit margin %11.30.1 9,910.8%  
BALANCE SHEET DATA
Current assets Rs m52,6236,852 768.0%   
Current liabilities Rs m52,0226,711 775.2%   
Net working cap to sales %1.03.3 29.9%  
Current ratio x1.01.0 99.1%  
Inventory Days Days120161 74.3%  
Debtors Days Days76318 23.9%  
Net fixed assets Rs m85,0163,673 2,314.6%   
Share capital Rs m846317 267.3%   
"Free" reserves Rs m45,3763,761 1,206.5%   
Net worth Rs m46,2224,078 1,133.6%   
Long term debt Rs m41,1151,671 2,460.8%   
Total assets Rs m142,43212,633 1,127.5%  
Interest coverage x4.01.0 390.3%   
Debt to equity ratio x0.90.4 217.1%  
Sales to assets ratio x0.40.3 126.4%   
Return on assets %6.93.4 201.2%  
Return on equity %14.70.1 12,463.0%  
Return on capital %14.27.7 184.9%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m14,580964 1,512.5%   
Fx outflow Rs m3,600607 593.0%   
Net fx Rs m10,980357 3,076.5%   
CASH FLOW
From Operations Rs m8,9421,345 664.9%  
From Investments Rs m-47,070-2,256 2,086.8%  
From Financial Activity Rs m34,174-1,200 -2,848.3%  
Net Cashflow Rs m-3,655-2,111 173.2%  

Share Holding

Indian Promoters % 71.5 4.5 1,578.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.0 -  
FIIs % 12.6 1.4 933.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 94.1 9.4%  
Shareholders   26,511 20,807 127.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  WYETH LTD  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 18, 2019 03:33 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - SUN PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS